<DOC>
	<DOC>NCT00337662</DOC>
	<brief_summary>The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.</brief_summary>
	<brief_title>Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients must demonstrate acute psychopathologic severity criteria and be at least moderately ill. Patients must have experienced an exacerbation of their illness within the previous 2 weeks. Patients in whom a switch to another antipsychotic medication is acutely indicated. Patients who are deemed nonresponsive to risperidone or olanzapine. Patients who have been hospitalized for greater than 2 weeks immediately prior to Visit 1. Patients having received olanzapine or risperidone in the past 30 days. Treatment with clozapine within 1 year prior to Visit 1. Diagnosis of substanceinduced psychosis by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSMIV) criteria within 7 days of Visit 1 (or at any time during the study), or confirmed on clinical grounds within 72 hours subsequent to Visit 1 (or at any time during the study). A diagnosis of Parkinson's disease, dementiarelated psychosis, or related disorders.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>